<DOC>
	<DOCNO>NCT00658333</DOCNO>
	<brief_summary>To determine conversion enteric coat MPA allows escalate dose mycophenolic acid ( MPA ) tolerate patient experience gastrointestinal ( GI ) symptom</brief_summary>
	<brief_title>A Study Designed Compare Tolerability Increased Dose Enteric-coated Mycophenolate Acid ( MPA ) Renal Transplant Patients Whose Dose Mycophenolate Mofetil ( MMF ) Was Reduced Due Gastrointestinal Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion : Recipients first second cadaveric , live unrelated living relate kidney transplant . Patients reduce daily dose ( 500mg 1500mg ) MMF exist tolerable control gastrointestinal symptom . Recipients least 4 week post renal transplantation stable renal function . Exclusion criterion : Multi organ transplant previous transplant organ kidney History GI disorder prior transplant Evidence GI disorder induce infection , underlie medical condition , con med MMF Modification GI med MMF dose within one week Evidence graft rejection , treatment acute rejection , unstable renal function within 1 week ( baseline ) visit Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Renal transplant recipient</keyword>
	<keyword>Gastrointestinal symptom associate MMF therapy</keyword>
</DOC>